Illumina Inc ILMN

NAS: ILMN | ISIN: US4523271090   28/10/2025
97,80 USD (-2,54%)
(-2,54%)   28/10/2025

15 oktober 2025 · Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights · Persbericht

15 oktober 2025 · Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot · Persbericht

14 oktober 2025 · Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025 · Persbericht

1 oktober 2025 · Illumina launches new business to accelerate technology and data-driven discovery · Persbericht

23 september 2025 · Illumina advances personalized cancer care with new pharma development partnerships · Persbericht

23 september 2025 · Vooruitblik op Amerika · Bolero.be

Voor de bel Amerikaanse futures en beursopening Op basis van de futures wordt een licht hogere opening voor de Amerikaanse aandelenmarkt voorspeld, na een technologiegedreven rally die de belangrijkste indexen voor de derde...

18 september 2025 · Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine · Persbericht

8 september 2025 · Lancement d'Illumina® Protein Prep pour améliorer les connaissances protéomiques et faciliter les découvertes et le développement de médicaments · Persbericht

3 september 2025 · Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development · Persbericht

31 juli 2025 · Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025 · Persbericht

30 juli 2025 · Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling · Persbericht

10 juli 2025 · Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025 · Persbericht

10 juli 2025 · Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year · Persbericht

23 juni 2025 · Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy · Persbericht

10 juni 2025 · lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics · Persbericht

29 mei 2025 · Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis · Persbericht

28 mei 2025 · Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies · Persbericht

14 mei 2025 · Illumina To Webcast Upcoming Investor Conference · Persbericht

13 mei 2025 · Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications · Persbericht

8 mei 2025 · Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 · Persbericht

Mijn selecties